Is Fabino Enter overvalued or undervalued?

As of 18 September 2025, the valuation grade for Fabino Enter has moved from expensive to very expensive. This indicates a significant shift in the company's perceived value, suggesting it is overvalued. The current PE ratio stands at 5.35, while the EV to EBITDA ratio is also at 6.75, both of which are relatively low compared to peers. However, the PEG ratio is notably at 0.00, which raises concerns about future growth expectations.
In comparison to its peers, Fabino Enter's valuation metrics are starkly lower than those of Sun Pharma Industries, which has a PE ratio of 34.46, and Divi's Lab, with a PE ratio of 70.44. This disparity highlights that Fabino Enter is not only overvalued but also lacks the growth potential that its peers exhibit. Additionally, the company's recent stock performance has been underwhelming, with a year-to-date return of -22.55% compared to a 6.24% gain in the Sensex, reinforcing the notion that the stock is not performing well in the current market environment.